BioInfra Co.,Ltd. Logo

BioInfra Co.,Ltd.

Offers cancer screening blood tests and provides CRO services to the pharmaceutical industry.

199730 | KO

Overview

Corporate Details

ISIN(s):
KR7199730003
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 흥덕중앙로 120 4층, 5층, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioInfra Co., Ltd. is a global healthcare and biotechnology company focused on advancing human health through innovative solutions for disease prevention and treatment. The company's core activities are centered on two primary business segments: diagnostics development and contract research organization (CRO) services. Its flagship product is a proprietary multi-biomarker blood test, a screening technology designed for the early detection of risk for eight major types of cancer. The company's CRO division provides comprehensive support to the pharmaceutical industry, offering services that include Phase 1 clinical trials, bioequivalence testing, immunoassays, and pharmaceutical quality inspections.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 763.0 KB
2025-06-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 83.8 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 754.8 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 30.2 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 18.1 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 103.0 KB
2025-03-14 00:00
Annual Report
사업보고서 (2024.12)
Korean 933.5 KB
2025-03-10 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.3 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 16.5 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 100.1 KB
2025-02-06 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB
2024-12-10 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-12-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 677.6 KB
2024-08-09 00:00
Interim Report
반기보고서 (2024.06)
Korean 665.6 KB

Automate Your Workflow. Get a real-time feed of all BioInfra Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioInfra Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioInfra Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bon Natural Life Ltd Logo
Bio-manufactures natural plant ingredients for fragrances, supplements, and immunity solutions.
United States of America
BON
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina
BSNL
Boundless Bio, Inc. Logo
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and genetically driven cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
United States of America
DRUG
BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America
BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea
003000
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America
BNR
C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America
CCCC

Talk to a Data Expert

Have a question? We'll get back to you promptly.